Pulse Biosciences Inc
$ 20.19
-5.74%
23 Feb - close price
- Market Cap 958,234,000 USD
- Current Price $ 20.19
- High / Low $ 21.54 / 19.32
- Stock P/E N/A
- Book Value 1.37
- EPS -1.14
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.49 %
- ROE -0.87 %
- 52 Week High 26.30
- 52 Week Low 12.56
About
Pulse Biosciences, Inc. is a bioelectrical medicine startup. The company is headquartered in Hayward, California.
Analyst Target Price
$22.00
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-10-29 | 2025-08-12 | 2025-05-05 | 2025-03-26 | 2024-10-30 | 2024-08-19 | 2024-05-07 | 2024-03-28 | 2023-11-13 | 2023-08-10 | 2023-05-11 | 2023-03-30 |
| Reported EPS | -0.29 | -0.28 | -0.2502 | -0.3124 | -0.2076 | -0.1991 | -0.1837 | -0.2167 | -0.19 | -0.22 | -0.26 | -0.25 |
| Estimated EPS | -0.31 | -0.26 | None | -0.24 | -0.24 | -0.2 | -0.24 | -0.24 | -0.22 | -0.22 | -0.22 | -0.24 |
| Surprise | 0.02 | -0.02 | 0 | -0.0724 | 0.0324 | 0.0009 | 0.0563 | 0.0233 | 0.03 | 0 | -0.04 | -0.01 |
| Surprise Percentage | 6.4516% | -7.6923% | None% | -30.1667% | 13.5% | 0.45% | 23.4583% | 9.7083% | 13.6364% | 0% | -18.1818% | -4.1667% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: PLSE
2026-02-21 08:07:53
Wall Street Zen has upgraded Pulse Biosciences (NASDAQ:PLSE) from a "sell" to a "hold" rating, leading to a consensus "Hold" rating for the stock with an average price target of $30. The company reported mixed Q4 results, beating EPS expectations but missing revenue, while showcasing strong clinical data for its endocardial nPulse catheter. Despite positive clinical updates, recent insider selling activity, including a 20,000-share sale by Kevin Danahy, might be a concern for investors.
2026-02-20 21:06:24
Pulse Biosciences has granted equity inducement awards to two new employees for up to 19,000 shares of common stock, in accordance with Nasdaq Listing Rule 5635(c)(4). These stock options have an exercise price of $4.18 per share and will vest over four years, subject to continued employment. The awards are part of the company's 2017 Inducement Equity Incentive Plan, aiming to attract and retain talent.
2026-02-20 21:05:23
Pulse Biosciences, Inc. has granted equity inducement awards to two new employees as per Nasdaq Listing Rule 5635(c)(4). These awards, approved on February 18, 2026, consist of options to purchase up to 19,000 shares of common stock at an exercise price of $25.46 per share, vesting over four years. This action is intended to incentivize their employment with the company.
2026-02-20 16:14:16
Shares of Pulse Biosciences Inc (PLSE) gapped down by 12.20% to $22.02 on February 20, after reaching an intraday low of $21.70. This price is 16.27% below its 52-week high and 75.32% above its 52-week low. Analysts have an average target price of $26.00 for PLSE, implying an 18.07% upside, and a consensus "Buy" recommendation.
2026-02-19 23:56:54
Pulse Biosciences, Inc (PLSE) reported a Q4 loss of $0.26 per share, beating the Zacks Consensus Estimate of a $0.32 loss. The company also surpassed revenue estimates with $0.26 million, compared to zero revenue a year ago. Despite a mixed estimate revisions trend, the stock has gained 85.4% year-to-date and currently holds a Zacks Rank #3 (Hold).
2026-02-19 22:08:08
Pulse Biosciences Inc. is set to announce its fourth-quarter and full-year 2025 results, with investors keenly watching how the company plans to translate recent clinical successes into commercial traction. Analysts expect a wider loss per share but a significant revenue rebound, following a clinical data release that caused a 70% stock surge. Key areas of focus for investors include the timeline for their pivotal NANOPULSE-AF study, the durability of their efficacy compared to competitors, and the company's cash runway and funding strategy, especially after recent insider sales.
